Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
CharlestonPharma
AddedFeb 15, 2024
UpdatedJun 18, 2026
CharlestonPharma

CharlestonPharma

CharlestonPharma LLC: Innovating in biotechnology, developing therapeutic antibodies for cancer care.

HQ
Charleston, SC, US
Founded
2010
Overview
Compare
Fundraising
Employees
Website

CharlestonPharma LLC, founded with a mission to innovate in biotechnology, focuses on developing therapeutic antibodies for cancer care. The company specializes in creating fully human monoclonal antibodies targeting the cell surface receptor nucleolin. Their flagship product, CP101.2C8, is an IgG1 monoclonal antibody designed to destabilize oncogenic mRNAs and induce apoptosis in various tumor cells. CharlestonPharma aims to provide advanced therapeutic options and related diagnostic tests for cancer patients and healthcare providers.

Notable figures affiliated with CharlestonPharma include leading scientists and industry experts in oncology and biotechnology. The company has attracted significant investment from venture capital firms specializing in life sciences. Key achievements include preclinical success with CP101.2C8, demonstrating its potential to target both hematological and solid tumors effectively. CharlestonPharma's innovative approach has the potential to make a substantial impact on cancer treatment, offering new hope to patients and advancing the field of therapeutic antibodies.

CharlestonPharma - Similar Companies

Camino Pharma logo

Camino Pharma

caminopharma.com

Cello Therapeutics logo

Cello Therapeutics

cellothera.com

Onchilles Pharma logo

Onchilles Pharma

Carisma Therapeutics logo

Carisma Therapeutics

carismatx.com

NantBio logo

NantBio

Cullinan Oncology logo

Cullinan Oncology

Oncolix logo

Oncolix

Celltheon logo

Celltheon

celltheon.com

Checkpoint Therapeutics logo

Checkpoint Therapeutics

checkpointtx.com

Cargene logo

Cargene

cargene.com

CBA Pharma logo

CBA Pharma

cbapharma.com

Karyopharm Therapeutics logo

Karyopharm Therapeutics

karyopharm.com

OncoResponse logo

OncoResponse

CarthroniX logo

CarthroniX

carthronix.com

Chlorogen logo

Chlorogen

chlorogen.com

CharlestonPharma - Quick Facts

Who are CharlestonPharma's competitors?

Companies similar to CharlestonPharma include Camino Pharma, Cello Therapeutics, Onchilles Pharma and Carisma Therapeutics.

When was CharlestonPharma founded?

CharlestonPharma was founded in 2010.

Where is CharlestonPharma's headquarters located?

CharlestonPharma's headquarters is located in Charleston, SC, US.

When was CharlestonPharma's last funding round?

CharlestonPharma's most recent funding round was for $450k (USD) in February 2018.

How much has CharlestonPharma raised to-date?

As of Feb 26, 2018, CharlestonPharma has raised a total of $4.4M (USD).

How many employees does CharlestonPharma have?

CharlestonPharma has 3 employees as of Feb 4, 2024.

CharlestonPharma - Classification

Ownership
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • United States
Revenue
  • Recurring
Customer
  • Enterprise
Main Product
  • Therapeutic Antibodies
Tags
  • Healthtech
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 325000Chemical Manufacturing
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 2830Drugs
  • 2834Pharmaceutical Preparations